Compare FWRD & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | SIGA |
|---|---|---|
| Founded | 1981 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.4M | 309.8M |
| IPO Year | 2024 | 2016 |
| Metric | FWRD | SIGA |
|---|---|---|
| Price | $14.24 | $3.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $37.50 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 378.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ 88.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $6.66 | $224.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.86 | $3.89 |
| 52 Week High | $32.47 | $9.62 |
| Indicator | FWRD | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 31.22 |
| Support Level | $9.47 | N/A |
| Resistance Level | $23.55 | $4.84 |
| Average True Range (ATR) | 0.96 | 0.12 |
| MACD | 0.42 | -0.03 |
| Stochastic Oscillator | 99.12 | 22.58 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.